GlassScriptPhysician profile
Jose D Morgan
NPI 1801180450
$1,135.30
in general payments reported to CMS, 2019-2025
17 companies · $73.04 in 2025
The $73.04 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2023: $128 · 2024: $591 · 2025: $73.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $215.03 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Metuchen Pharmaceuticals | $171.92 | 2019 | |
| Amgen INC. | $165.84 | 2023-2024 | Otezla, Repatha |
| Exact Sciences Corporation | $158.29 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $128.96 | 2019 | |
| Lilly USA, LLC | $79.89 | 2023-2024 | Jardiance, Zepbound, Mounjaro |
| Horizon Therapeutics Plc | $41.95 | 2019 | |
| Kyowa Kirin, INC. | $27.86 | 2024 | Crysvita |
| Dexcom, INC. | $23.66 | 2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $19.93 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $19.33 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.46 | 2024 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $17.51 | 2024 | Gvoke Hypopen |
| Pfizer INC. | $17.00 | 2023 | |
| Idorsia Pharmaceuticals US INC | $15.59 | 2023 | Quviviq |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14.08 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.